CU23276B7 - PéPTIDOS A PARTIR DEL ANTICUERPO 16/6ID PARA TRATAR LUPUS ERITEMATOSO SISTéMICO - Google Patents

PéPTIDOS A PARTIR DEL ANTICUERPO 16/6ID PARA TRATAR LUPUS ERITEMATOSO SISTéMICO

Info

Publication number
CU23276B7
CU23276B7 CU20030184A CU20030184A CU23276B7 CU 23276 B7 CU23276 B7 CU 23276B7 CU 20030184 A CU20030184 A CU 20030184A CU 20030184 A CU20030184 A CU 20030184A CU 23276 B7 CU23276 B7 CU 23276B7
Authority
CU
Cuba
Prior art keywords
antibody
periods
treat systemic
systemic erythematosus
sequence
Prior art date
Application number
CU20030184A
Other languages
English (en)
Inventor
Edna Mozes
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of CU23276B7 publication Critical patent/CU23276B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

PÉptidos sintÉticos de al menos 12 y de mAximo 30 residuos de aminoAcidos que comprenden una secuencia que consiste de, o que se encuentra en, una region determinante complementariedad (CDR) encontrada en la cadena pesada o en la cadena ligera del anticuerpo monoclonal 16/61d anti-ADN de humano, o una secuencia obtenida mediante el reemplazo y/o la delecion y/o la adicion de uno o mAs residuos de aminoAcidos a dicha secuencia, y sales, derivados químicos y polímeros de dichos pÉptidos que pueden ser utilizados para la inmunomodulacion de las respuestas asociadas con el lupus sistÉmico eritematoso.
CU20030184A 2001-02-26 2003-08-20 PéPTIDOS A PARTIR DEL ANTICUERPO 16/6ID PARA TRATAR LUPUS ERITEMATOSO SISTéMICO CU23276B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CU23276B7 true CU23276B7 (es) 2008-04-09

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030184A CU23276B7 (es) 2001-02-26 2003-08-20 PéPTIDOS A PARTIR DEL ANTICUERPO 16/6ID PARA TRATAR LUPUS ERITEMATOSO SISTéMICO

Country Status (29)

Country Link
US (2) US20040127408A1 (es)
EP (1) EP1370575B1 (es)
JP (1) JP4316886B2 (es)
KR (1) KR100860735B1 (es)
CN (1) CN1309733C (es)
AT (1) ATE346094T1 (es)
AU (1) AU2002233618B2 (es)
BR (1) BR0207586A (es)
CA (1) CA2439051C (es)
CR (1) CR7058A (es)
CU (1) CU23276B7 (es)
DE (1) DE60216243T2 (es)
DK (1) DK1370575T3 (es)
EA (1) EA009465B1 (es)
EC (1) ECSP034743A (es)
ES (1) ES2275832T3 (es)
HK (1) HK1059790A1 (es)
HR (1) HRP20030667A2 (es)
HU (1) HU230372B1 (es)
IL (3) IL141647A0 (es)
IS (1) IS6908A (es)
MX (1) MXPA03007622A (es)
NO (1) NO331820B1 (es)
NZ (1) NZ527499A (es)
PL (1) PL373520A1 (es)
PT (1) PT1370575E (es)
SI (1) SI1370575T1 (es)
WO (1) WO2002067848A2 (es)
ZA (1) ZA200305874B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033377A2 (en) * 2000-09-20 2002-04-25 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
AU2004206842A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
WO2008144041A1 (en) * 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
CN110139659B (zh) * 2017-01-05 2023-07-28 耶达研究及发展有限公司 用于治疗干燥综合征的肽
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
WO1999031066A1 (en) * 1997-12-18 1999-06-24 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
AU2004206842A1 (en) 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US7294687B2 (en) 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Also Published As

Publication number Publication date
IL141647A0 (en) 2002-03-10
HK1059790A1 (en) 2004-07-16
NO20033718D0 (no) 2003-08-21
CN1309733C (zh) 2007-04-11
ATE346094T1 (de) 2006-12-15
IS6908A (is) 2003-08-11
MXPA03007622A (es) 2004-09-14
BR0207586A (pt) 2006-11-07
DK1370575T3 (da) 2007-01-29
HUP0600778A3 (en) 2012-09-28
WO2002067848A2 (en) 2002-09-06
SI1370575T1 (sl) 2007-04-30
AU2002233618B2 (en) 2006-12-21
HUP0600778A2 (en) 2007-01-29
CA2439051C (en) 2010-02-02
DE60216243D1 (de) 2007-01-04
NO331820B1 (no) 2012-04-10
KR20030092004A (ko) 2003-12-03
EP1370575A2 (en) 2003-12-17
US7858738B2 (en) 2010-12-28
EP1370575A4 (en) 2004-09-29
CN1503806A (zh) 2004-06-09
ECSP034743A (es) 2004-01-28
KR100860735B1 (ko) 2008-09-29
JP4316886B2 (ja) 2009-08-19
HRP20030667A2 (en) 2005-06-30
JP2005505493A (ja) 2005-02-24
PL373520A1 (en) 2005-09-05
CR7058A (es) 2004-11-01
ZA200305874B (en) 2005-08-31
NZ527499A (en) 2005-12-23
CA2439051A1 (en) 2002-09-06
US20080119390A1 (en) 2008-05-22
NO20033718L (no) 2003-10-09
IL157550A (en) 2010-05-31
EA200300939A1 (ru) 2004-12-30
PT1370575E (pt) 2007-01-31
EP1370575B1 (en) 2006-11-22
IL157550A0 (en) 2004-03-28
WO2002067848A3 (en) 2002-12-12
US20040127408A1 (en) 2004-07-01
HU230372B1 (hu) 2016-03-29
ES2275832T3 (es) 2007-06-16
DE60216243T2 (de) 2007-10-31
EA009465B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
CY1115702T1 (el) Αντισωμα υποκαθιστον τη λειτουργια του παραγοντα πηξεως αιματος viii
CU23276B7 (es) PéPTIDOS A PARTIR DEL ANTICUERPO 16/6ID PARA TRATAR LUPUS ERITEMATOSO SISTéMICO
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
CR6425A (es) Anticuerpos monoclonales humanos de ctla-4
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
ATE483472T1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
CO5050255A1 (es) Anticuerpo especifico de fap con productividad mejorada
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
CY1115778T1 (el) Πολλαπλες παραλλαγες της πρωτεϊνης μηνiγγιτιδοκοκκου νμβ1870
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
RS50477B (sr) Anti-il-12 antitela, kompozicije, metode i njihove upotrebe
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
DE60135330D1 (de) Reinigung von xanthophyllen aus ringelblumenextrakten mit hohem chlorophyllgehalt
CY1112041T1 (el) Ενδοφθαλμιος φακος
CY1108257T1 (el) In vitro ανασυσταμενες στιβαδες ανθρωπινου κερατοειδικου επιθηλιου και μεθοδος παραγωγης αυτων
BR0309850A (pt) Ensaios de qualidade para células apresentando antìgeno

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)